# Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

> **NCT04526210** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Wilson Disease

## Interventions

- **DRUG:** ALXN1840
- **DRUG:** Bupropion Hydrochloride

## Key facts

- **NCT ID:** NCT04526210
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-05-28
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526210, "Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04526210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*